Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease

Mult Scler Relat Disord. 2019 Jan:27:406-408. doi: 10.1016/j.msard.2018.12.005. Epub 2018 Dec 3.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Alemtuzumab / adverse effects*
  • Alemtuzumab / therapeutic use*
  • Alopecia / etiology*
  • Alopecia / pathology
  • Female
  • Humans
  • Immunologic Factors / adverse effects*
  • Immunologic Factors / therapeutic use*
  • Male
  • Multiple Sclerosis, Relapsing-Remitting / complications
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Vitiligo / complications
  • Vitiligo / pathology

Substances

  • Immunologic Factors
  • Alemtuzumab